ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
3,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5,1,Diabetic hyperglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
6,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
6,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
7,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
7,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
9,1,Alcohol intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
10,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
11,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
13,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
14,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
15,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
16,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
17,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
18,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
19,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
19,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
19,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
20,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
21,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
22,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
22,2,Headache,Headaches NEC,Headaches,Nerv,N
23,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
24,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
25,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
26,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
26,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
27,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
28,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
28,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
29,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
30,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
31,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,Y
32,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
32,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
34,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
35,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
36,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
36,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
37,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
38,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
39,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
40,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
41,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
42,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
42,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
42,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
42,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
43,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
44,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
45,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
46,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
47,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
48,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
49,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
50,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
51,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
52,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
53,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
54,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
55,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
56,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
57,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
57,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
58,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
58,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
59,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
60,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
60,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
60,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
60,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
60,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
61,1,Device failure,Device issues NEC,Device issues,Prod,N
61,2,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
62,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
63,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
64,1,Device failure,Device issues NEC,Device issues,Prod,N
64,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
64,3,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
65,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
66,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
67,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
68,1,Device failure,Device issues NEC,Device issues,Prod,N
68,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
69,1,Amyloidosis,Amyloidoses,Immune disorders NEC,Immun,N
70,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
71,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
71,2,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
72,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
73,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
74,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
75,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
76,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
77,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
78,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
78,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
79,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
79,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
81,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
82,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
83,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
84,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
85,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
85,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
86,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
87,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
88,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
89,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
90,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
91,1,Injection site abscess sterile,Injection site reactions,Administration site reactions,Genrl,N
92,1,Injection site abscess sterile,Injection site reactions,Administration site reactions,Genrl,N
93,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
94,1,Device failure,Device issues NEC,Device issues,Prod,N
94,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
95,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
96,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
97,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
98,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
99,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
100,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
101,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
102,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
103,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
104,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
105,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
105,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
106,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
107,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
108,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
108,2,Prostatic disorder,"Prostatic signs, symptoms and disorders NEC",Prostatic disorders (excl infections and inflammations),Repro,N
109,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
110,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
111,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
111,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
111,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
112,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
113,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
113,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
114,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
115,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
116,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
117,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
118,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
118,2,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
119,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
119,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
120,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
120,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
120,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
121,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
122,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
122,2,Orbital oedema,"Orbital structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
122,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
122,4,Skin degenerative disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
122,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
123,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
124,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
125,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
126,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
126,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
126,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
126,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
126,5,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
127,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
128,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
129,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
130,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
130,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
131,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
132,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
133,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
134,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
135,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
136,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
136,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
136,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
137,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
138,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
138,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
138,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
139,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
139,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
140,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
141,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
141,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
141,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
141,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
141,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
141,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
141,7,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
142,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
142,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
143,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
143,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
144,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
145,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
145,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
146,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
147,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
147,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
148,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
149,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
150,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
151,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
152,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
153,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
154,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
155,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
156,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
157,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
158,1,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
158,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
158,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
158,4,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
159,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
159,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
160,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
160,2,Nosocomial infection,Infectious transmissions,Ancillary infectious topics,Infec,Y
160,3,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
160,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
161,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
162,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
162,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
163,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
163,3,Odynophagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
163,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
163,5,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
164,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
164,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
165,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
166,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
166,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
167,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
168,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
168,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
168,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
168,4,Dysmenorrhoea,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
168,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
168,6,Headache,Headaches NEC,Headaches,Nerv,N
168,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
169,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
169,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
169,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
170,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
171,1,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
171,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
171,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
172,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
173,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
173,2,Headache,Headaches NEC,Headaches,Nerv,N
174,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
174,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
174,3,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
174,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
175,1,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
175,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
175,3,Blood prolactin decreased,Pituitary analyses anterior,Endocrine investigations (incl sex hormones),Inv,N
175,4,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
175,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
175,6,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
175,7,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
175,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
175,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
175,10,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
175,11,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
175,12,Headache,Headaches NEC,Headaches,Nerv,N
175,13,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
175,14,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
175,15,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
175,16,Hypopituitarism,Anterior pituitary hypofunction,Hypothalamus and pituitary gland disorders,Endo,N
175,17,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
175,18,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
175,19,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
175,20,Pituitary infarction,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
175,21,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
175,22,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
176,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
177,1,Device failure,Device issues NEC,Device issues,Prod,N
178,1,Granuloma,Inflammations,General system disorders NEC,Genrl,N
178,2,Panniculitis,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
179,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
179,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
179,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
179,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
179,5,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
179,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
179,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
180,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
181,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
182,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
182,2,Neuroglycopenia,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,Y
183,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
183,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
184,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
184,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
185,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
186,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
187,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
187,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
187,3,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
188,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
188,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
189,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
190,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
191,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
192,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
192,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
193,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
193,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
194,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
195,2,Epigastric discomfort,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
195,3,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
196,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
197,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
198,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
198,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
199,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
199,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
199,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
200,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
200,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
201,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
202,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
202,2,Rhinalgia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
203,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
203,2,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
203,3,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
203,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
204,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
205,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
205,2,Hyperinsulinaemic hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
205,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
206,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
207,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
207,2,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
208,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
209,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
209,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
209,3,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
209,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
210,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
210,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
210,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
211,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
211,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
211,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
211,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
212,1,Anti-insulin antibody positive,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
212,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
213,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
214,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
214,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
214,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
215,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
215,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
215,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
215,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
215,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
215,6,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
216,1,"Hallucination, auditory",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
217,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
218,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
219,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
219,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
219,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
219,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
220,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
221,1,Hyperparathyroidism primary,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
221,2,Parathyroid tumour benign,Endocrine neoplasms benign NEC,Endocrine neoplasms benign,Neopl,N
222,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
222,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
223,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
223,2,Device leakage,Device issues NEC,Device issues,Prod,N
223,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
224,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
224,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
225,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
226,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
226,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
226,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
226,4,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
226,5,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
226,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
227,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
227,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
227,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
227,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
228,1,Blood glucose false positive,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
228,2,Device interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
228,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
228,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
229,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
230,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
230,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
231,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
231,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
232,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
232,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
232,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
233,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
233,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
233,3,Panniculitis,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
234,1,Acarodermatitis,Ectoparasitic infestations,Ectoparasitic disorders,Infec,N
234,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
234,3,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
234,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
234,5,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
235,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
236,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
236,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
236,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
236,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
237,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
237,2,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
237,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
237,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
237,5,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
237,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
237,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
237,8,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
238,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
238,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
238,3,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
238,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
238,5,Labelled drug-disease interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
238,6,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
238,7,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
238,8,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
238,9,Osmotic demyelination syndrome,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
238,10,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
238,11,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
238,12,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
239,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
239,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
239,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
240,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
241,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
241,2,Blood insulin abnormal,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
241,3,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
241,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
241,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
241,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
241,7,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
241,8,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
241,9,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
242,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
242,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
243,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
243,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
244,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
244,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
245,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
245,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
245,3,Insulin autoimmune syndrome,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
246,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
246,2,Hyperglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
246,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
247,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
247,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
248,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
248,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
249,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
250,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
250,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
250,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
251,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
251,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
251,3,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
251,4,Polyhydramnios,Amniotic fluid and cavity disorders of pregnancy NEC,"Placental, amniotic and cavity disorders (excl haemorrhages)",Preg,N
252,1,Cardiac murmur,Cardiac auscultatory investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
252,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
252,3,Gangrene neonatal,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
252,4,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
252,5,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
253,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
254,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
254,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
254,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
254,6,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
254,7,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
254,8,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
254,9,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
254,10,Low carbohydrate diet,Dietary and nutritional therapies,Therapeutic procedures and supportive care NEC,Surg,N
254,11,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
254,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
254,13,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
254,14,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
254,15,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
254,16,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
254,17,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
254,18,Symptom recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,19,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
255,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
255,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
255,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
256,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
256,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
256,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
256,4,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
256,5,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
256,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
256,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
256,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
257,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
257,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
258,1,Allergic reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
258,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
258,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
258,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
258,5,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
258,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
258,7,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
258,8,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
258,9,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
258,10,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
258,11,Migraine,Migraine headaches,Headaches,Nerv,N
258,12,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
258,13,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
258,14,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
258,15,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
258,16,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
258,17,Sleep disorder due to a general medical condition,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
258,18,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
258,19,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
259,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
259,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
259,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
259,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
259,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
259,6,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
259,7,Therapeutic product effect variable,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
259,8,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
260,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
260,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
260,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
260,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
260,6,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
260,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
260,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
260,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
260,11,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
260,12,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
260,13,Headache,Headaches NEC,Headaches,Nerv,N
260,14,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
260,15,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
260,16,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
260,17,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
260,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
261,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
261,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
261,3,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
262,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
262,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
262,3,Milk allergy,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
263,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
263,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
263,3,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
264,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
264,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
264,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
265,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
265,2,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
265,3,Product delivery mechanism issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
265,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
266,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
266,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
266,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
266,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
267,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
268,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
268,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
268,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
268,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
268,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
268,6,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
268,7,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
269,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
269,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
269,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
269,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
269,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
269,6,Near death experience,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
270,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
270,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
271,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
271,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,3,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
271,4,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
271,5,Suspected product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
272,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
273,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
273,2,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
273,3,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
273,4,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
273,5,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
273,6,Suspected product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
273,7,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
274,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
275,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
275,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
276,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
276,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
276,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
276,4,Hyperinsulinaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
276,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
276,6,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
277,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
277,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
277,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
277,4,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
277,5,Suspected product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
